Caroline Loew - Dec 14, 2023 Form 4 Insider Report for Mural Oncology plc (MURA)

Role: Chief Executive Officer, Director
Signature: /s/ Maiken Keson-Brookes, attorney-in-fact for Caroline Loew
Stock symbol: MURA
Transactions as of: Dec 14, 2023
Transactions value $: $0
Form type: 4
Date filed: 12/18/2023, 04:30 PM
Previous filing: Nov 7, 2023
Next filing: Mar 4, 2024

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	MURA	Ordinary Shares	Award	$0	+167K		$0.00	167K	Dec 14, 2023	Direct	F1
transaction	MURA	Ordinary Shares	Award	$0	+37.2K		$0.00	37.2K	Dec 14, 2023	Direct	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	MURA	Stock Option (right to buy)	Award		+380K			380K	Dec 14, 2023	Ordinary Shares	380K	$3.61	Direct	F3, F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents a restricted stock unit award originally granted by Alkermes plc ("Alkermes") that was converted into a restricted stock unit ("RSU") award of Mural Oncology plc (the "Issuer") in connection with the spin-off of the Issuer from Alkermes (the "Spin-off"). Consists of ordinary shares issuable under 167,276 RSUs. Each RSU represents the right to receive one ordinary share of the Issuer upon vesting. These RSUs are scheduled to vest with respect to 25% of the underlying ordinary shares on each of the first four anniversaries of July 5, 2023, subject to the reporting person's continued service with the Issuer.
F2	Consists of ordinary shares issuable under 37,171 RSUs. Each RSU represents the right to receive one ordinary share of the Issuer upon vesting. These RSUs are scheduled to vest with respect to 25% of the underlying ordinary shares on each of the first four anniversaries of December 14, 2023, subject to the reporting person's continued service with the Issuer.
F3	Represents an option award originally granted by Alkermes that was converted into an option award of the Issuer in connection with the Spin-off.
F4	This option was granted on December 14, 2023. The option is scheduled to vest with respect to 25% of the underlying ordinary shares on each of the first four anniversaries of July 5, 2023, subject to the reporting person's continued service with the Issuer.